These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Fouquet G; Guidez S; Herbaux C; Van de Wyngaert Z; Bonnet S; Beauvais D; Demarquette H; Adib S; Hivert B; Wemeau M; Berthon C; Terriou L; Coiteux V; Macro M; Decaux O; Facon T; Huglo D; Leleu X Clin Cancer Res; 2014 Jun; 20(12):3254-60. PubMed ID: 24714772 [TBL] [Abstract][Full Text] [Related]
69. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Cserti C; Haspel R; Stowell C; Dzik W Transfusion; 2007 Mar; 47(3):511-4. PubMed ID: 17319833 [TBL] [Abstract][Full Text] [Related]
70. Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Song JW; Yang WI; Kim JS Ann Hematol; 2014 Nov; 93(11):1867-77. PubMed ID: 24947797 [TBL] [Abstract][Full Text] [Related]
71. [Biochemical and immunological findings of multiple myeloma]. Asaoku H Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270 [TBL] [Abstract][Full Text] [Related]
72. Comparison of the Freelite serum free light chain (SFLC) assay with serum and urine electrophoresis/immunofixation and the N Latex FLC assay. Sasson SC; McGill K; Wienholt L; Carr A; Brown DA; Kelleher AD; Breit SN; Sewell WA Pathology; 2015 Oct; 47(6):564-9. PubMed ID: 26352111 [TBL] [Abstract][Full Text] [Related]
73. Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Dejoie T; Corre J; Caillon H; Moreau P; Attal M; Loiseau HA Leukemia; 2019 Feb; 33(2):313-318. PubMed ID: 30573778 [TBL] [Abstract][Full Text] [Related]
74. Combined analysis using extended renal reference range of serum free light chain ratio and serum protein electrophoresis improves the diagnostic accuracy of multiple myeloma in renal insufficiency. Park JW; Kim YK; Bae EH; Ma SK; Kim SW Clin Biochem; 2012 Jul; 45(10-11):740-4. PubMed ID: 22503879 [TBL] [Abstract][Full Text] [Related]
75. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation. Tovar N; Fernández de Larrea C; Elena M; Cibeira MT; Aróstegui JI; Rosiñol L; Filella X; Yagüe J; Bladé J Biol Blood Marrow Transplant; 2012 Jul; 18(7):1076-9. PubMed ID: 22430087 [TBL] [Abstract][Full Text] [Related]
76. [Determination of light chains in serum]. Hansen CT; Nielsen L; Münster AM; Abildgaard N Ugeskr Laeger; 2010 Aug; 172(34):2302-5. PubMed ID: 20727297 [TBL] [Abstract][Full Text] [Related]
77. Serum free light chain immunoassay as an adjunct to serum protein electrophoresis and immunofixation electrophoresis in the detection of multiple myeloma and other B-cell malignancies. Harding SJ; Mead GP; Bradwell AR; Berard AM Clin Chem Lab Med; 2009; 47(3):302-4. PubMed ID: 19676141 [TBL] [Abstract][Full Text] [Related]
78. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755 [TBL] [Abstract][Full Text] [Related]